{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:20:11Z","timestamp":1792797611979,"version":"4.5.0"},"reference-count":35,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Urine drug testing is frequently ordered by health care providers. Immunoassays are widely used for drug testing, yet have potential limitations, including variable cross-reactivity. The last decade has seen worsening of a prescription drug abuse epidemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To use data from a College of American Pathologists proficiency testing survey, Urine Drug Testing, Screening, to determine and summarize the characteristics, performance, and limitations of immunoassays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Seven years of proficiency surveys were reviewed (2011\u20132017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Rapid growth was seen in participant volumes for specific immunoassays for synthetic opioids (eg, buprenorphine, fentanyl, oxycodone) and 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d). Participant volumes remained high for immunoassays targeting less commonly abused drugs such as barbiturates and phencyclidine. For opiate immunoassays, the number of laboratories using a 2000 ng\/mL positive cutoff remained stable, and an increasing number adopted a 100 ng\/mL cutoff. Opiate and amphetamine immunoassays showed high variability in cross-reactivity for drugs other than the assay calibrator. Assays targeting a single drug or metabolite generally performed well on drug challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Survey results indicate strong clinical interest in urine drug testing and some adoption of new assays. However, urine drug testing availability does not parallel prevailing patterns of drug prescribing and abuse patterns. In particular, specific immunoassays for synthetic opioids and a lower positive cutoff for opiate immunoassays may be underused, whereas immunoassays for barbiturates, methadone, propoxyphene, and phencyclidine may be overused. Laboratories are encouraged to review their test menu, cutoffs, and assay performance and adjust their test offerings based on clinical needs and technical capabilities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0562-cp","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T11:28:01Z","timestamp":1563362881000},"page":"177-184","source":"Crossref","is-referenced-by-count":17,"title":["Interpretation and Utility of Drug of Abuse Screening Immunoassays: Insights From Laboratory Drug Testing Proficiency Surveys"],"prefix":"10.5858","volume":"144","author":[{"given":"Matthew D.","family":"Krasowski","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City (Dr Krasowski); the Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, Salt Lake City (Dr McMillin); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Melanson); the Proficiency Testing Division, College of American Pathol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn A.","family":"McMillin","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City (Dr Krasowski); the Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, Salt Lake City (Dr McMillin); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Melanson); the Proficiency Testing Division, College of American Pathol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy E. F.","family":"Melanson","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City (Dr Krasowski); the Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, Salt Lake City (Dr McMillin); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Melanson); the Proficiency Testing Division, College of American Pathol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Dizon","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City (Dr Krasowski); the Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, Salt Lake City (Dr McMillin); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Melanson); the Proficiency Testing Division, College of American Pathol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbarajean","family":"Magnani","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City (Dr Krasowski); the Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, Salt Lake City (Dr McMillin); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Melanson); the Proficiency Testing Division, College of American Pathol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L. H.","family":"Snozek","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City (Dr Krasowski); the Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, Salt Lake City (Dr McMillin); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Melanson); the Proficiency Testing Division, College of American Pathol"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"issue":"3","key":"2020081300433160700_i1543-2165-144-2-177-b01","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11718","article-title":"Trends in illicit drug use among smokers and nonsmokers in the United States, 2002\u20132014","volume":"79","author":"Moeller","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"2020081300433160700_i1543-2165-144-2-177-b02","unstructured":"Park-Lee E , LipariRN, HeddenSL, KroutilLA, PorterJD. Receipt of Services for Substance Use and Mental Health Issues Among Adults: Results from the 2016 National Survey on Drug Use and Health. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2017. CBHSQ data review."},{"issue":"1","key":"2020081300433160700_i1543-2165-144-2-177-b03","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2105\/AJPH.2017.304142","article-title":"Increasing prescription opioid and heroin overdose mortality in the United States, 1999\u20132014: an age-period-cohort analysis","volume":"108","author":"Huang","year":"2018","journal-title":"Am J Public Health"},{"issue":"7","key":"2020081300433160700_i1543-2165-144-2-177-b04","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/add.14144","article-title":"Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999\u20132015","volume":"113","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"issue":"12","key":"2020081300433160700_i1543-2165-144-2-177-b05","doi-asserted-by":"crossref","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants\u2014United States, 2015\u20132016","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"14","key":"2020081300433160700_i1543-2165-144-2-177-b06","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/jama.2015.11859","article-title":"Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003\u20132013","volume":"314","author":"Han","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"2020081300433160700_i1543-2165-144-2-177-b07","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2020081300433160700_i1543-2165-144-2-177-b08","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2020081300433160700_i1543-2165-144-2-177-b09","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1080\/15563650.2017.1388087","article-title":"2016 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th annual report","volume":"55","author":"Gummin","year":"2017","journal-title":"Clin Toxicol (Phila)"},{"key":"2020081300433160700_i1543-2165-144-2-177-b10","unstructured":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017. HHS publication SMA 17-5044, NSDUH series H-52."},{"issue":"3","key":"2020081300433160700_i1543-2165-144-2-177-b11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cll.2012.06.004","article-title":"The utility of immunoassays for urine drug testing","volume":"32","author":"Melanson","year":"2012","journal-title":"Clin Lab Med"},{"issue":"6","key":"2020081300433160700_i1543-2165-144-2-177-b12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10408363.2017.1385053","article-title":"and oral fluid drug testing in support of pain management","volume":"54","author":"Kwong","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1","key":"2020081300433160700_i1543-2165-144-2-177-b13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clinic Proc"},{"issue":"6","key":"2020081300433160700_i1543-2165-144-2-177-b14","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1213\/ANE.0000000000002565","article-title":"Role of urine drug testing in the current opioid epidemic","volume":"125","author":"Mahajan","year":"2017","journal-title":"Anesth Analg"},{"issue":"6","key":"2020081300433160700_i1543-2165-144-2-177-b15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1373\/clinchem.2008.118638","article-title":"Chemoinformatic methods for predicting interference in drug of abuse\/toxicology immunoassays","volume":"55","author":"Krasowski","year":"2009","journal-title":"Clin Chem"},{"issue":"7","key":"2020081300433160700_i1543-2165-144-2-177-b16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J Anal Toxicol"},{"issue":"5","key":"2020081300433160700_i1543-2165-144-2-177-b17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5858\/134.5.735","article-title":"Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys","volume":"134","author":"Melanson","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2020081300433160700_i1543-2165-144-2-177-b18","article-title":"ClinCalc DrugStats database: Free U.S. outpatient drug usage statistics","year":"2018"},{"issue":"2","key":"2020081300433160700_i1543-2165-144-2-177-b19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jat\/bkv133","article-title":"A retrospective analysis of urine drugs of abuse immunoassay true positive rates at a national reference laboratory","volume":"40","author":"Johnson-Davis","year":"2016","journal-title":"J Anal Toxicol"},{"key":"2020081300433160700_i1543-2165-144-2-177-b20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-227X-9-5","article-title":"Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse\/toxicology screening in emergency medicine","volume":"9","author":"Krasowski","year":"2009","journal-title":"BMC Emerg Med"},{"issue":"1","key":"2020081300433160700_i1543-2165-144-2-177-b21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/bks083","article-title":"Urine drug testing of chronic pain patients, V: prevalence of propoxyphene following its withdrawal from the United States market","volume":"37","author":"Puet","year":"2013","journal-title":"J Anal Toxicol"},{"issue":"50\u201351","key":"2020081300433160700_i1543-2165-144-2-177-b22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths\u2014United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2020081300433160700_i1543-2165-144-2-177-b23","first-page":"134","article-title":"Impact of expanding ELISA screening in DUID investigations to include carisoprodol\/meprobamate and zolpidem","volume":"41","author":"Lu","year":"2017","journal-title":"J Anal Toxicol"},{"issue":"2","key":"2020081300433160700_i1543-2165-144-2-177-b24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/anatox\/35.2.108","article-title":"Validation of a new homogeneous immunoassay for the detection of carisoprodol in urine","volume":"35","author":"Wang","year":"2011","journal-title":"J Anal Toxicol"},{"key":"2020081300433160700_i1543-2165-144-2-177-b25","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2382","article-title":"Detectability of fentanyl and designer fentanyls in urine by 3 commercial fentanyl immunoassays","author":"Helander","year":"2018","journal-title":"Drug Test Anal"},{"issue":"11\u201312","key":"2020081300433160700_i1543-2165-144-2-177-b26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.cca.2011.01.029","article-title":"A new automated urine fentanyl immunoassay: technical performance and clinical utility for monitoring fentanyl compliance","volume":"412","author":"Snyder","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2020081300433160700_i1543-2165-144-2-177-b27","first-page":"313","article-title":"Validation of the Neogen\u00ae Fentanyl ELISA kit for blood and urine","volume":"41","author":"Tiscione","year":"2017","journal-title":"J Anal Toxicol"},{"issue":"1\u20133","key":"2020081300433160700_i1543-2165-144-2-177-b28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.forsciint.2010.07.022","article-title":"Development of a homogeneous immunoassay for the detection of fentanyl in urine","volume":"206","author":"Wang","year":"2011","journal-title":"Forensic Sci Int"},{"issue":"4","key":"2020081300433160700_i1543-2165-144-2-177-b29","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays","volume":"9","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Test Anal"},{"issue":"9","key":"2020081300433160700_i1543-2165-144-2-177-b30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jat\/bku103","article-title":"Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay","volume":"38","author":"Wang","year":"2014","journal-title":"J Anal Toxicol"},{"key":"2020081300433160700_i1543-2165-144-2-177-b31","doi-asserted-by":"crossref","first-page":"2374289518811797","DOI":"10.1177\/2374289518811797","article-title":"A difficult challenge for the clinical laboratory: accessing and interpreting manufacturer cross-reactivity data for immunoassays used in urine drug testing","volume":"5","author":"Reschly-Krasowski","year":"2018","journal-title":"Acad Pathol"},{"issue":"6","key":"2020081300433160700_i1543-2165-144-2-177-b32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/jat\/23.6.549","article-title":"Experience with a urine opiate screening and confirmation cutoff of 2000 ng\/mL","volume":"23","author":"Fraser","year":"1999","journal-title":"J Anal Toxicol"},{"key":"2020081300433160700_i1543-2165-144-2-177-b33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.forsciint.2014.04.042","article-title":"Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content","volume":"241","author":"Smith","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"2","key":"2020081300433160700_i1543-2165-144-2-177-b34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13181-015-0477-9","article-title":"Acetyl fentanyl, a novel fentanyl analog, causes 14 overdose deaths in Rhode Island, March\u2013May 2013","volume":"11","author":"Lozier","year":"2015","journal-title":"J Med Toxicol"},{"issue":"3","key":"2020081300433160700_i1543-2165-144-2-177-b35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jat\/14.3.160","article-title":"Detection of fentanyl and its analogs by enzyme-linked immunosorbent assay","volume":"14","author":"Ruangyuttikarn","year":"1990","journal-title":"J Anal Toxicol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/177\/2500839\/arpa_2018-0562-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/177\/2500839\/arpa_2018-0562-cp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:47Z","timestamp":1764790607000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/2\/article-p177.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,7,17]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0562-cp","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]}}}